Stemcell Technologies and Brigham and Women’s Hospital Signs Exclusive License Agreement for Kidney Organoid Technology

 Stemcell Technologies and Brigham and Women’s Hospital Signs Exclusive License Agreement for Kidney Organoid Technology

Stemcell Technologies and Brigham and Women’s Hospital Signs Exclusive License Agreement for Kidney Organoid Technology

Shots:

  • The agreement will focus on commercialization of kidney organoid technology, for generation of human pluripotent stem cell-derived kidney organoids
  • This technology enables the growth of organoids/ mini-organs, having key features of renal development and physiology in vitro and is developed by one of the professor at Brigham and Women’s Hospital
  • The kidney organoids provide reproductive and adaptable framework for forming renal physiology, injury and disease at developmental stages

Click here to read full press release/ article | Ref:  Stemcell Technologies | Image: Kevin Hardiman

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post